P2RX7 and autoimmune disease: P2X7 receptor (P2X7R) antagonists have been previously investigated in phase 2 clinical trials for treatment of inflammatory and autoimmune diseases, including chronic obstructive pulmonary disorder, rheumatoid arthritis and Crohn’s disease (Arulkumaran et al., 2011; Keystone et al., 2012).